150 related articles for article (PubMed ID: 17495956)
1. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Mathieu V; Le Mercier M; De Neve N; Sauvage S; Gras T; Roland I; Lefranc F; Kiss R
J Invest Dermatol; 2007 Oct; 127(10):2399-410. PubMed ID: 17495956
[TBL] [Abstract][Full Text] [Related]
2. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Le Mercier M; Mathieu V; Haibe-Kains B; Bontempi G; Mijatovic T; Decaestecker C; Kiss R; Lefranc F
J Neuropathol Exp Neurol; 2008 May; 67(5):456-69. PubMed ID: 18431251
[TBL] [Abstract][Full Text] [Related]
3. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
5. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
6. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide for advanced, metastatic melanoma.
Cohen MH; Johnson JR; Middleton MR
J Clin Oncol; 2000 May; 18(10):2185. PubMed ID: 10811684
[No Abstract] [Full Text] [Related]
8. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
9. Evidence of galectin-1 involvement in glioma chemoresistance.
Le Mercier M; Lefranc F; Mijatovic T; Debeir O; Haibe-Kains B; Bontempi G; Decaestecker C; Kiss R; Mathieu V
Toxicol Appl Pharmacol; 2008 Jun; 229(2):172-83. PubMed ID: 18313712
[TBL] [Abstract][Full Text] [Related]
10. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
[TBL] [Abstract][Full Text] [Related]
12. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
13. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Zuckerman JE; Hsueh T; Koya RC; Davis ME; Ribas A
J Invest Dermatol; 2011 Feb; 131(2):453-60. PubMed ID: 20944646
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
15. Enhancing melanoma treatment with resveratrol.
Osmond GW; Augustine CK; Zipfel PA; Padussis J; Tyler DS
J Surg Res; 2012 Jan; 172(1):109-15. PubMed ID: 20855085
[TBL] [Abstract][Full Text] [Related]
16. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Luo Y; Ellis LZ; Dallaglio K; Takeda M; Robinson WA; Robinson SE; Liu W; Lewis KD; McCarter MD; Gonzalez R; Norris DA; Roop DR; Spritz RA; Ahn NG; Fujita M
J Invest Dermatol; 2012 Oct; 132(10):2440-2450. PubMed ID: 22622430
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide as prophylaxis for melanoma brain metastases.
Conill C; González-Cao M; Jorcano S; Puig S; Malvehy J; Martí R; Castel T
Melanoma Res; 2004 Feb; 14(1):73-4. PubMed ID: 15091198
[No Abstract] [Full Text] [Related]
18. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Treudler R; Georgieva J; Geilen CC; Orfanos CE
J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
[TBL] [Abstract][Full Text] [Related]
19. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Ryabaya O; Prokofieva A; Khochenkov D; Abramov I; Zasedatelev A; Stepanova E
Oncol Rep; 2018 Jul; 40(1):385-394. PubMed ID: 29749510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
